Product Details
Product Name:
CAY10462 |
CAS No.:
502656-68-0 |
Purity:
99.49% |
Supply Ability:
10g |
Release date:
2024/11/19 |
Product Introduction
Bioactivity
Name | CAY10462 |
Description | CAY10462 (CTK8E8405) is an effective and selective inhibitor of the 20-HETE synthase CYP4A11 with an IC50 of 8.8 nM. CAY10462 exhibits nearly 200 times less potent for 1A, 1C, and 3A CYP450 enzymes. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 12 mg/mL (33.3 mM), Sonication is recommended.
|
Keywords | CAY-10462 | CTK8E-8405 | CAY 10462 | CTK8E 8405 |
Inhibitors Related | Tebuconazole | 1-Ethynylnaphthalene | Diflubenzuron | Apigenin | Gemfibrozil | Fenofibrate | 1-Aminobenzotriazole | Methoxsalen | Naringin | Naringenin | Tauroursodeoxycholate | Doxepin hydrochloride |
Related Compound Libraries | Bioactive Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Anti-Metabolism Disease Compound Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
-
CAS:880635-03-0
$32.00 / 1mg
-
CAS:530-14-3
$41.00 / 1mg
-
CAS:666859-49-0
$82.00 / 1mg
Recommended supplier
Product name |
Price |
|
Suppliers |
Update time |
|
$/ |
|
Anhui Ruihan Technology Co., Ltd
|
2023-08-21 |